

WHAT IS IMMUNOTHERAPY?

Immunotherapy is a treatment method that uses a patient's own immune system to fight and kill cancer cells more effectively. The immune system keeps track of all of the substances normally found in the body. Any new substance that the immune system does not recognize raises an alarm, causing the immune system to attack it. Most of the time, it is more difficult for the immune system to recognize cancer cells as foreign, which allows them to grow and spread throughout the body. Immunotherapy treatments and drugs help the immune system to recognize and locate cancer cells and strengthen its response to help it destroy them.

Immunotherapy is available in different types of treatment, some are FDA approved and some are available through a clinical trial. Examples of types of immunotherapy include:

- Monoclonal antibodies
- Bispecific T-cell engaging antibodies
- Checkpoint inhibitors
- Therapeutic vaccines
- CAR T-cells

NORTHSIDE'S IMMUNOTHERAPY PROGRAM

Northside Hospital Cancer Institute's (NHCI) Immunotherapy Program physicians are experts in administering immunotherapy cancer treatments including CAR (chimeric antigen receptor) T-cell therapy. We offer a distinctive program backed by clinical expertise and innovative facilities to meet the unique needs of patients undergoing this breakthrough treatment option.

Northside's Immunotherapy Program participates in CAR T-cell pharmaceutical industry clinical research trials that allow our patients to have access to leading-edge treatment.

With access to state-of-the-art diagnostic testing and facilities, comprehensive patient-centered care and a highly trained immunotherapy multidisciplinary team, we provide patients with exceptional quality care that results in outstanding survival outcomes and patient satisfaction.

For more information on available clinical trials visit:

bmtga.com/research/open-clinical-trials

NORTHSIDE HOSPITAL CANCER INSTITUTE

The Immunotherapy Program at Northside Hospital Cancer Institute (NHCI) provides patients with the exceptional quality care needed to treat their malignancies. As a statewide leader of the National Cancer Institute Oncology Research Program (NCORP), our physicians provide access to groundbreaking clinical trials. We offer a continuum of care that encompasses the entire patient experience - from diagnosis and treatment to support and survivorship.

NORTHSIDE HOSPITAL CANCER INSTITUTE

BUILT TO BEAT CANCER

WE ARE HERE FOR YOU.

Physicians Available 24/7

Phone: 404-255-1930 | Fax: 404-255-1939


5670 Peachtree Dunwoody Road
Suite 1000
Atlanta, GA 30342

northside.com/immunotherapy
bmtga.com

**The Blood & Marrow
Transplant Group**
O F G E O R G I A



IMMUNOTHERAPY PROGRAM




**NORTHSIDE HOSPITAL
CANCER INSTITUTE**
IMMUNOTHERAPY PROGRAM

How Does Autologous CAR T-Cell Therapy Work?

This highly specialized 5-step process takes place over several weeks:


STEP 1

T-Cell Collection: Collecting T-cells (called leukopheresis/apheresis), is a simple procedure, similar to donating blood.




STEP 2

Engineer-Reprogram: T-cells are shipped to a manufacturer to produce special receptors on their surface called chimeric antigen receptors, or CARs. This enables T-cells to better recognize, kill and destroy cancer cells.




STEP 3

Expansion: T-cells grow and expand until they multiply into the billions. The manufacturing process may take several weeks to complete. Then they are shipped back to NHCI's hematopoietic stem cell laboratory.




STEP 4

Chemotherapy and Infusion: Patients receive a brief course of chemotherapy prior to CAR T-cell infusion. Chemotherapy creates space in the immune system so that the CAR T-cells can grow, flourish and kill the cancer cells. CAR T-cell infusion occurs after the completion of chemotherapy.



STEP 5

Destruction of Cancer Cells: Over the next several days, weeks and months, CAR T-cells will multiply, kill and destroy tumor cells. Patients are monitored for side effects and will remain in close proximity to the hospital for approximately 30 days after the infusion.



CAR T-CELL THERAPY AT NORTHSIDE

Northside Hospital Cancer Institute is among a select number of centers in the country to offer CAR T-cell therapy, one of the most promising cell-based cancer immunotherapies available. The Food and Drug Administration (FDA) has approved CAR T-cell therapy for certain diagnoses, giving hope to patients who previously did not have it.



WHAT MAKES NORTHSIDE DIFFERENT FROM OTHER CAR T-CELL CENTERS?

At Northside, our Program is able to provide patients with the following:

- Within 5-10 business days of initial referral, the relapsed/refractory patient can be evaluated by Northside's Immunotherapy/CAR T-cell physicians
- With on-site apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within 1-2 weeks of new patient consultations
- Continuous communication with referring hematologists/oncologists to ensure bridging therapy is initiated, if applicable
- Dedicated nurse coordinators who will organize and coordinate care from new patient consultation through post CAR T-cell therapy follow-up
- Dedicated financial specialists who are able to quickly obtain CAR T-cell therapy financial approval